Rochester, NY 6/8/2009 10:18:43 PM
Morning Stocks Trending Down - Sourced WhisperfromWallStreet.com - XTENT, Inc.,XTNT - Emisphere Technologies, Inc.,EMIS - Somaxon Pharmaceuticals, Inc.,SOMX
XTENT, Inc. - Emisphere Technologies, Inc - Somaxon Pharmaceuticals, Inc.
Morning Stocks Trending Down - Sourced WhisperfromWallStreet.com - XTENT, Inc.,XTNT - Emisphere Technologies, Inc.,EMIS - Somaxon Pharmaceuticals, Inc.,SOMX
XTENT, Inc.,XTNT
Last Trade: 1.50
Day's Range: 1.33 - 1.74
52wk Range: 0.15 - 3.42
Volume: 1,934,035
On June 3, 2009, the board of directors of XTENT, Inc. set July 9, 2009 as the date for the special meeting of the Company's stockholders at which stockholders will vote on a plan of complete liquidation and dissolution of the Company.
On June 4, 2009, the Company issued a press release announcing that the U.S. Food and Drug Administration has granted conditional approval of the Company's pivotal clinical program for its Custom NX Drug Eluting Stent System. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.
ABOUT
XTENT, Inc., a development stage medical device company, focuses on developing and commercializing customizable drug eluting stent systems for the treatment of coronary artery diseases. It offers Custom NX 36, which is used to treat single or multiple lesions; and Custom NX 60 that is designed to give physicians a suitable length stent to treat one long lesion or multiple smaller lesions. The company's NX DES systems are in custom care clinical trials. Its drug eluting stent systems are designed to enable physicians to customize length and diameter of the stent at the site of the diseased section of the artery or lesion. The company develops 36 and 60 millimeter stent systems based on its proprietary technology platform. XTENT, Inc. was founded in 2002 and is based in Menlo Park, California.
---
If you are viewing this press release you are obviously interested in making money in the stock market. In today’s market investors need every tool available. WhisperfromWallStreet.com sends FREE alerts to our subscribers on stocks that we feel are ready to move within hours or days. So far in 2009 we have sent 36 stock alerts to our clients and the average price gain has been 88%. To add additional profits to your portfolio please take a minute and sign up for our free alerts. There is no risk to you and you will see just how accurate we are in our alerts.
Investors sign up for our FREE alerts at http://whisperfromwallstreet.com
---
Emisphere Technologies, Inc.,EMIS
Shares of Emisphere Technologies Inc. fell Monday after Nasdaq told the biotechnology company its stock will be delisted from the exchange because of its low market value.
Shares fell 31 cents, or 23.3 percent, to $1.02 in morning trading. The stock has traded between 42 cents and $4.45 per share over the last 52 weeks.
The shares will be delisted June 9, the company said. Emisphere said the shares should be eligible for trading on the over-the-counter bulletin board.
ABOUT
Emisphere Technologies, Inc., a biopharmaceutical company, focuses on the delivery of therapeutic molecules and pharmaceutical compounds using its 'eligen' technology. The eligen technology could be applied to the oral route of administration, as well as the other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal, or transdermal. The company's product pipeline includes Oral Salmon Calcitonin, which is in Phase III clinical trials for the treatment of osteoporosis and osteoarthritis; Oral Recombinant Parathyroid Hormone, which is in Phase I clinical trials for the treatment of osteoporosis; and Oral Heparin that is in Phase III clinical trials, as well as Oral Low Molecular Weight Heparin, which is in Phase I clinical trials for the treatment of cardiovascular diseases.
Last Trade: 1.05
Day's Range: 0.9010 - 1.31
52wk Range: 0.42 - 4.45
Volume: 577,204
---
Somaxon Pharmaceuticals, Inc.,SOMX
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. The company has completed four Phase III clinical trials for its lead product candidate, Silenor (doxepin hydrochloride) for the treatment of insomnia. Somaxon Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Diego, California.
Last Trade: 1.15
Day's Range: 1.01 - 1.45
52wk Range: 0.18 - 4.85
Volume: 527,411
---
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
